9801152-1

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 39/00, C07K 16/18 — A1

(11) International Publication Number: WO 97/02045

(43) International Publication Date: 23 January 1997 (23.01.97)

(21) International Application Number: PCT/GB96/01614

(22) International Filing Date: 5 July 1996 (05.07.96)

(30) Priority Data:
9513733.7 5 July 1995 (05.07.95) GB

(71) Applicant *(for all designated States except US)*: UNIVERSITY OF BRISTOL [GB/GB]; Senate House, Tyndall Avenue, Clifton, Bristol BS8 1TH (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: WILLIAMS, Neil, Andrew [GB/GB]; 16 Old Coach Road, Cross, Axbridge, Somerset BS26 2EF (GB). HIRST, Timothy, Raymond [GB/GB]; 30 Albert Road, Clevedon, North Somerset BS21 7RR (GB). NASHAR, Toufic, Osman [LB/GB]; University of Bristol, School of Medical Services, Dept. of Pathology & Microbiology, University Walk, Bristol BS8 1TD (GB).

(74) Agent: NASH, David, Allan; Haseltine Lake & Co., Hazlitt House, 28 Southampton Buildings, Chancery Lane, London WC2A 1AT (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

30 MAR 1998
REGISTRY OF TRADE MARKS & PATENTS SINGAPORE

(54) Title: THERAPEUTIC AGENTS AND AUTOIMMUNE DISEASES

(57) Abstract

There is disclosed the use, as an agent in the treatment or the prevention of an autoimmune disease, of: (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity. These agents may also be used in the treatment of human T cell leukaemia, in the prevention of transplant rejection or GVHD or in a vaccination method for vaccinating a mammalian subject.

REPLACED SHEETS SG

☐ Description : paged ..... to paged .....

☑ Claim(s) : paged 44 to paged 46

☐ Drawing(s) : paged ..... to paged .....

☐ Abstract : paged ..... to paged .....